Maze Therapeutics Announces Positive Phase 1 Results for MZE829 in APOL1 Kidney Disease
Maze Therapeutics, a biopharmaceutical company focused on developing precision medicines using human genetics, has announced positive results from the Phase 1 clinical trial of MZE829 in healthy volunteers. MZE829 is…
Pharmacy Automation Innovations Reduce Operational Costs
Amid fluctuating market conditions and regulatory changes, pharmacies can leverage automated production to enhance efficiency, boost profitability, and substantially lower operational costs. Pharmacy automation provider JFCRx™ has launched TruCard™, a…
Agomab Secures $89 Million in Series D Funding for Fibrosis Pipeline Expansion
Agomab Therapeutics NV has announced an $89 million (€82.1 million) Series D financing round, featuring contributions from new investors Sanofi and Invus, alongside support from existing investors. Agomab Therapeutics plans…
PFD Week 2024: Model Predicts Women’s Success with First-Line Incontinence Treatment
Axena Health, Inc., a medical device company focused on female pelvic health, has announced the development of a machine learning model that could help clinicians create personalized treatments for female…
Hesperos and UCF Create Human iPSC Myelination Model for Peripheral Nervous System Research
Hesperos, a leader in human biology recreation with its Human-on-a-Chip® platform, has made a significant advancement by developing a human induced pluripotent stem cell (iPSC)-derived model of peripheral myelination. This…
Precision BioSciences Shares Preclinical Data on ARCUS Gene Editing at ESGCT 31st Congress
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage gene editing company using its proprietary ARCUS® platform for advanced in vivo gene editing therapies, announced a poster presentation at the European Society…
PharmaJet Study: Improved Polio Immunization with Tropis® ID Delivery
PharmaJet®, a company focused on enhancing injectable performance with its needle-free technology, has announced the results of an implementation study in Nigeria. This study evaluated the impact of administering the…
Prisma Health and Upfront Healthcare Activate Nearly One Million Patients, Says Leading Journal
Upfront Healthcare’s collaboration with Prisma Health, which has successfully engaged nearly one million patients, is featured in the latest issue of The Healthcare Administration Leadership & Management (HALM) Journal. Published…
Two-Year Data Confirm Efficacy and Safety of Tibial NeuroModulation for Urgency Urinary Incontinence
BlueWind Medical, Ltd., a pioneer in implantable Tibial NeuroModulation (iTNM) and the creator of the Revi® System, has announced the presentation of new two-year data from its OASIS pivotal study.…
Simulations Plus Releases Q4 and Fiscal 2024 Financial Results
Simulations Plus, Inc. (Nasdaq: SLP), a top provider of biosimulation and performance solutions for the biopharma industry, has announced its financial results for the fourth quarter and fiscal year 2024,…
Rubedo Life Sciences Expands into Europe Ahead of First Clinical Trial
Rubedo Life Sciences, a biopharmaceutical company dedicated to developing advanced therapies targeting senescent cells linked to age-related diseases, has announced the opening of its European headquarters and clinical operations in…
CareMonitor Selects 8×8 CPaaS for Key Patient Interactions
8×8, Inc. (NASDAQ: EGHT), a prominent provider of business communications, customer experience (CX), and CPaaS platforms, has announced that CareMonitor has successfully implemented 8×8 CPaaS to enhance critical patient interactions.…